SCYNEXIS (SCYX) Projected to Release Earnings on Wednesday

SCYNEXIS (NASDAQ:SCYX) is expected to post its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.72) per share and revenue of $0.13 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Monday, August 10th. The company reported $0.63 EPS for the quarter, topping the consensus estimate of ($0.51) by $1.14. The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.08 million. On average, analysts expect SCYNEXIS to post ($1.60) EPS for the current fiscal year and ($0.80) EPS for the next fiscal year.

SCYNEXIS Stock Up 1.1%

SCYX opened at $3.81 on Tuesday. The company has a fifty day moving average of $4.53 and a 200 day moving average of $5.51. SCYNEXIS has a fifty-two week low of $3.53 and a fifty-two week high of $9.12.

Wall Street Analysts Forecast Growth

Several analysts have commented on SCYX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SCYNEXIS in a research note on Thursday, October 22nd. Brookline Capital Markets restated a “buy” rating on shares of SCYNEXIS in a research report on Friday, July 31st. Wall Street Zen raised SCYNEXIS from a “strong sell” rating to a “hold” rating in a report on Sunday, August 16th. Finally, Guggenheim reiterated a “buy” rating and issued a $33.00 target price (up from $24.00) on shares of SCYNEXIS in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, SCYNEXIS presently has an average rating of “Hold” and an average target price of $33.00.

SCYNEXIS Company Profile

SCYNEXIS, Inc is a biotechnology company focused on developing and commercializing innovative antifungal therapies for the treatment of serious and common fungal infections. The company’s research platform is centered on ibrexafungerp, a novel triterpenoid antifungal designed to inhibit glucan synthase, an enzyme important to the formation of fungal cell walls.

SCYNEXIS’s lead product, BREXAFEMME (ibrexafungerp tablets), is an oral antifungal approved in the United States for the treatment of vaginal yeast infections, also known as vulvovaginal candidiasis.